explore -WSS

explore

author：Wikipedia 2025-09-02 08:18:37 - browse：9

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： There’s no way to know how good AI health technologies are

focus

hotspot

WSS

How the messy conversation about Dolly changed bioethics

Female surgeons have lower rates of long

What's changing in Medicare's open enrollment this year?

How the messy conversation about Dolly changed bioethics

Better Therapeutics data on benefit with GLP

Bernie Sanders bashes nonprofit hospitals over their tax breaks

hotspot

explore

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

David Liu startup to focus on CRISPR delivery

ChatGPT in medicine: STAT answers readers' burning questions

Cancer cells are shown to suck energy source from immune cells

Cancer drug shortages should be causing more outrage

Takeaways from AdvaMed, the largest medical devices conference

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare to cover more brain scans related to Alzheimer’s drugs

Psychedelics group wrestles with new pharma identity

David Liu startup to focus on CRISPR delivery

focus

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Akili changes sales model for its ADHD video game treatment

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Female surgeons have lower rates of long

Transgender sports debate: Physicians say bans are health issue

'A game

focus

focus

hotspot

hotspot